Page 1,157«..1020..1,1561,1571,1581,159..1,1701,180..»

The most creative, patent-based technology firms – Industry Global News 24

Posted: Published on December 19th, 2019

Business4 Min read The most creative, patent-based technology firms Published On 19 Dec 2019 02:49 PM These and many other interesting insights come from the patent analysis research carried out by Swiss consulting firm EconSight, which first listed all the patents intended to protect particularly relevant inventions-in this case, described as innovations for the digitization of applied technology-using the PatentSight database. Companies must not only retain their creative strength; they must also continue to expand to take a leading position in the ranking compared to previous years. Key results from EconSight's patent analysis report that identifies the world's most innovative companies include: 38 of the world's most innovative companies are headquartered in the U.S., 21 in China, and 15 in Europe Continue reading

Posted in Medical Technology | Comments Off on The most creative, patent-based technology firms – Industry Global News 24

The Major Merger Reviews Of 2019 – Law360

Posted: Published on December 19th, 2019

Law360 (December 19, 2019, 9:31 AM EST) -- U.S. antitrust enforcers this year dusted off a never-before-used merger challenge authority, found themselves at diametric odds over a merger that could impact every American with a cellphone, carved out the nuances of their merger differences and navigated an extraordinary level of settlement scrutiny in court Continue reading

Posted in Medical Technology | Comments Off on The Major Merger Reviews Of 2019 – Law360

Study Finds Antibodies That Reduce Parkinson’s Alpha-synuclein Clumps – Parkinson’s News Today

Posted: Published on December 19th, 2019

Antibodies that selectively target the misfolded form of the alpha-synuclein protein that which underlies the development of Parkinsons disease reduced the formation of alpha-synuclein clumpsand improved dopamine levels in a mouse model. Continue reading

Posted in Parkinson's Treatment | Comments Off on Study Finds Antibodies That Reduce Parkinson’s Alpha-synuclein Clumps – Parkinson’s News Today

Things Lost and Things Gained – Parkinson’s News Today

Posted: Published on December 19th, 2019

Have you ever heard someone say that Parkinsons can be blamed for much and many a thing? I have. And why not blame our woes on this disease Continue reading

Posted in Parkinson's Treatment | Comments Off on Things Lost and Things Gained – Parkinson’s News Today

New Gene Therapy Method May Open BRAVE New World in Parkinson’s – Parkinson’s News Today

Posted: Published on December 19th, 2019

A new method allows researchers to develop adeno-associated virus (AVV) commonly used as the vehicle for gene therapies that accurately target and deliver genes to specific cells in the body. This new technology may be suitable to target dopaminergic neurons that are damaged in Parkinsons disease Continue reading

Posted in Parkinson's Treatment | Comments Off on New Gene Therapy Method May Open BRAVE New World in Parkinson’s – Parkinson’s News Today

Aspen Neuroscience Receives $6.5M for Parkinson’s Stem Cell Therapy – Parkinson’s News Today

Posted: Published on December 19th, 2019

Aspen Neuroscience, a new biotech company, has raised $6.5 million to develop cell therapies for Parkinsons disease using patients own cells. The company was co-founded by renowned stem cell scientists Jeanne F. Loring, PhD, and Andres Bratt-Leal, PhD, and initially supported by Summit for Stem Cell, a non-profit organization that provides a variety of services for Parkinsons patients. Continue reading

Posted in Parkinson's Treatment | Comments Off on Aspen Neuroscience Receives $6.5M for Parkinson’s Stem Cell Therapy – Parkinson’s News Today

Could It Be the Pseudobulbar Affect or Am I Just Happy? – Parkinson’s News Today

Posted: Published on December 19th, 2019

I was playing a nice, calm game of Hearts with my kids and grandkids when I started laughing. Again. My outburst was not out of the ordinary, unless somewhat irrepressible mirth counts as abnormal Continue reading

Posted in Parkinson's Treatment | Comments Off on Could It Be the Pseudobulbar Affect or Am I Just Happy? – Parkinson’s News Today

Caregivers of Patients With Recurrent Symptoms of Parkinson Disease Exposed to Greater Financial Burden, Loss of Employment – AJMC.com Managed Markets…

Posted: Published on December 19th, 2019

Caregivers of patients with Parkinson disease (PD) experiencing symptom recurrence after a period of symptom control, known as OFF periods, reported that PD had a greater impact on their paid employment through variables such as loss of earnings, loss of opportunities, or ability to maintain employment compared with caregivers for patients without OFF periods. Research presented at AMCP Nexus 2019 in National Harbor, Maryland, sought to assess the financial burden of caregivers for patients with PD (PwP) who are in OFF periods. Another study presented at the conference found that 56.3% of PwP undergoing OFF periods cited symptom recurrence as a major reason to stop working, 25.4 percentage points more than PwP without OFF periods (30.9%). Continue reading

Posted in Parkinson's Treatment | Comments Off on Caregivers of Patients With Recurrent Symptoms of Parkinson Disease Exposed to Greater Financial Burden, Loss of Employment – AJMC.com Managed Markets…

Oliver Sacks: A Bequest of Empathy and Candor – East Hampton Star

Posted: Published on December 19th, 2019

Oliver Sacks continued to write until a few days before his death, and three volumes of his essays have been published posthumously. As a medical doctor and a writer, [Oliver] Sacks achieved a level of popular renown rare among scientists, wrote Gregory Cowles in the neurologists New York Times obituary Continue reading

Posted in Parkinson's Treatment | Comments Off on Oliver Sacks: A Bequest of Empathy and Candor – East Hampton Star

Xeljanz XR Approved for Ulcerative Colitis – Monthly Prescribing Reference

Posted: Published on December 19th, 2019

The Food and Drug Administration (FDA) has approved Xeljanz XR (tofacitinib extended-release; Pfizer) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have an inadequate response or who are intolerant to tumor necrosis factor blockers. The approval of Xeljanz XR, which is available in 11mg and 22mg extended-release tablets, was based on data obtained from clinical trials evaluating Xeljanz (tofacitinib) in adult patients with moderately to severely active UC. The extended-release formulation now allows for once-daily dosing for induction and maintenance therapy. Continue reading

Posted in Ulcerative Colitis | Comments Off on Xeljanz XR Approved for Ulcerative Colitis – Monthly Prescribing Reference

Page 1,157«..1020..1,1561,1571,1581,159..1,1701,180..»